In a landmark decision, UK pharmaceutical giant GSK has announced a staggering $2.2 billion (£1.68 billion) settlement to resolve thousands of lawsuits in the U.S. linked to its discontinued heartburn medication, Zantac. The company reached agreements with 10 law firms representing around 80,000 claimants, effectively addressing 93% of all pending cases related to the drug.
In addition to the massive settlement, GSK will pay $70 million to settle a whistleblower complaint from a laboratory that accused the company of defrauding the U.S. government by downplaying the potential cancer risks associated with Zantac.
Despite the hefty payouts, GSK maintains it did not admit any wrongdoing, stating that there is “no consistent or reliable evidence” that Zantac increases cancer risk. However, the company acknowledged that settling these cases helps alleviate significant financial uncertainty moving forward.
Originally approved in the U.S. in 1983, Zantac quickly skyrocketed to become the world’s best-selling drug, raking in over $1 billion in annual sales within just five years. But in 2020, U.S. regulators pulled Zantac from shelves after concerns arose that a key ingredient, ranitidine, could transform into a potentially cancer-causing substance when exposed to heat. This decision sparked a wave of lawsuits against Zantac’s manufacturers.
The controversy surrounding Zantac led to UK doctors advising against its prescription as a precautionary measure in 2019. Other pharmaceutical giants like Pfizer and Sanofi have also settled their cases, while Boehringer Ingelheim has yet to announce any major settlements.
Interestingly, a new version of the drug, Zantac 360, which contains no ranitidine, is still available on the market today.
